O	0	3	The
O	4	10	effect
O	11	13	of
O	14	15	a
O	16	18	12
O	18	19	-
O	19	23	week
B-intervention	24	28	home
I-intervention	28	29	-
I-intervention	29	34	based
I-intervention	35	42	walking
I-intervention	43	50	program
O	51	53	on
O	54	62	reducing
B-condition	63	70	fatigue
O	71	73	in
B-eligibility	74	79	women
I-eligibility	80	84	with
I-eligibility	85	91	breast
I-eligibility	92	98	cancer
I-eligibility	99	109	undergoing
I-eligibility	110	122	chemotherapy
O	122	123	:
O	124	125	A
O	126	136	randomized
O	137	147	controlled
O	148	153	study
O	153	154	.

O	155	162	Fatigue
O	163	165	is
O	166	169	the
O	170	174	most
O	175	181	common
O	182	189	symptom
O	190	201	experienced
O	202	204	by
O	205	211	cancer
O	212	220	patients
O	221	227	during
O	228	237	treatment
O	238	241	and
O	242	245	can
O	246	250	last
O	251	255	long
O	256	261	after
O	262	272	completing
O	273	282	treatment
O	282	283	.

O	284	291	Fatigue
O	292	294	in
O	295	301	cancer
O	302	310	patients
O	311	314	who
O	315	319	have
O	320	329	completed
O	330	339	treatment
O	340	342	is
O	343	347	well
O	348	353	known
O	354	356	to
O	357	359	be
O	360	367	reduced
O	368	370	by
O	371	379	exercise
O	379	380	,
O	381	384	but
O	385	388	the
O	389	395	effect
O	396	398	of
O	399	407	exercise
O	408	410	on
O	411	419	reducing
O	420	427	fatigue
O	428	430	in
O	431	439	patients
O	440	445	under
O	446	455	treatment
O	456	459	has
O	460	464	been
O	465	477	inconsistent
O	477	478	.

O	479	482	The
O	483	491	purposes
O	492	494	of
O	495	499	this
O	500	505	study
O	506	510	were
O	511	513	to
O	514	521	examine
O	522	527	short
O	527	528	-
O	528	532	term
O	533	536	and
O	537	541	long
O	541	542	-
O	542	546	term
O	547	554	effects
O	555	557	of
O	558	560	an
O	561	573	individually
O	574	582	tailored
O	582	583	,
O	584	588	home
O	588	589	-
O	589	594	based
O	595	600	brisk
O	601	608	walking
O	609	616	program
O	617	619	on
O	620	628	reducing
O	629	636	fatigue
O	637	639	in
O	640	646	breast
O	647	653	cancer
O	654	662	patients
O	663	668	under
O	669	681	chemotherapy
O	681	682	.

O	683	686	For
O	687	691	this
O	692	702	randomized
O	703	713	controlled
O	714	719	trial
O	719	720	,
O	721	726	women
O	727	731	were
O	732	741	recruited
O	742	746	from
O	747	748	a
O	749	756	medical
O	757	763	center
O	764	766	in
B-location	767	775	northern
I-location	776	782	Taiwan
B-eligibility	783	785	if
I-eligibility	786	790	they
I-eligibility	791	795	were
I-eligibility	796	805	diagnosed
I-eligibility	806	810	with
I-eligibility	811	817	stages
I-eligibility	818	819	I
I-eligibility	819	820	-
I-eligibility	820	823	III
I-eligibility	824	830	breast
I-eligibility	831	837	cancer
I-eligibility	838	841	and
I-eligibility	842	853	experienced
I-eligibility	854	862	insomnia
I-eligibility	862	863	,
I-eligibility	864	871	fatigue
I-eligibility	871	872	,
I-eligibility	873	877	pain
I-eligibility	877	878	,
I-eligibility	879	881	or
I-eligibility	882	892	depressive
I-eligibility	893	901	symptoms
I-eligibility	902	907	after
I-eligibility	908	913	their
I-eligibility	914	919	first
I-eligibility	920	925	cycle
I-eligibility	926	928	of
I-eligibility	929	941	chemotherapy
O	941	942	.

O	943	953	Consenting
O	954	966	participants
O	967	968	(
O	968	969	N
O	970	971	=
B-total-participants	972	975	159
O	975	976	)
O	977	981	were
O	982	990	randomly
O	991	999	assigned
O	1000	1002	to
O	1003	1009	either
O	1010	1012	an
O	1013	1021	exercise
O	1022	1023	(
O	1023	1025	12
O	1025	1026	-
O	1026	1030	week
O	1031	1035	home
O	1035	1036	-
O	1036	1041	based
O	1042	1049	walking
O	1050	1057	program
O	1057	1058	)
O	1059	1064	group
O	1065	1066	(
O	1066	1067	n
O	1068	1069	=
B-intervention-participants	1070	1072	81
O	1072	1073	)
O	1074	1076	or
O	1077	1079	an
B-control	1080	1089	attention
I-control	1089	1090	-
I-control	1090	1097	control
I-control	1098	1103	group
O	1104	1105	(
O	1105	1106	n
O	1107	1108	=
B-control-participants	1109	1111	78
O	1111	1112	)
O	1112	1113	.

O	1114	1117	The
O	1118	1120	12
O	1120	1121	-
O	1121	1125	week
O	1125	1126	,
O	1127	1131	home
O	1131	1132	-
O	1132	1137	based
O	1138	1143	brisk
O	1144	1151	walking
O	1152	1159	program
O	1160	1167	started
O	1168	1170	on
O	1171	1174	the
O	1175	1180	first
O	1181	1184	day
O	1185	1187	of
O	1188	1191	the
O	1192	1197	third
O	1198	1210	chemotherapy
O	1211	1216	cycle
O	1216	1217	.

O	1218	1225	Fatigue
O	1226	1229	was
O	1230	1238	measured
O	1239	1241	by
O	1242	1245	the
O	1246	1251	Brief
O	1252	1259	Fatigue
O	1260	1269	Inventory
O	1269	1270	.

O	1271	1281	Covariates
O	1281	1282	,
O	1283	1284	i
O	1284	1285	.
O	1285	1286	e
O	1286	1287	.
O	1287	1288	,
O	1289	1299	functional
O	1300	1311	performance
O	1311	1312	,
O	1313	1318	sleep
O	1319	1330	disturbance
O	1330	1331	,
O	1332	1339	anxiety
O	1339	1340	,
O	1341	1351	depression
O	1351	1352	,
O	1353	1356	and
O	1357	1365	exercise
O	1365	1366	-
O	1366	1373	related
O	1374	1383	variables
O	1383	1384	,
O	1385	1389	were
O	1390	1394	also
O	1395	1403	measured
O	1403	1404	.

O	1405	1409	Data
O	1410	1414	were
O	1415	1424	collected
O	1425	1427	at
O	1428	1436	baseline
O	1436	1437	,
O	1438	1441	two
O	1442	1447	times
O	1448	1454	during
O	1455	1458	the
O	1459	1467	exercise
O	1468	1480	intervention
O	1480	1481	,
O	1482	1485	and
O	1486	1490	five
O	1491	1496	times
O	1497	1502	after
O	1503	1506	the
O	1507	1515	exercise
O	1516	1528	intervention
O	1529	1530	(
O	1530	1535	eight
O	1536	1541	times
O	1542	1544	in
O	1545	1550	total
O	1550	1551	)
O	1551	1552	.

O	1553	1556	The
O	1557	1564	effects
O	1565	1567	of
O	1568	1572	time
O	1572	1573	-
O	1573	1580	varying
O	1581	1584	and
O	1585	1589	time
O	1589	1590	-
O	1590	1599	invariant
O	1600	1610	predictors
O	1611	1613	on
O	1614	1621	fatigue
O	1622	1626	were
O	1627	1635	analyzed
O	1636	1638	by
O	1639	1649	multilevel
O	1650	1658	modeling
O	1658	1659	.

B-outcome	1660	1667	Fatigue
I-outcome	1668	1674	levels
O	1675	1684	increased
O	1685	1689	over
O	1690	1694	time
O	1695	1698	for
O	1699	1703	both
O	1704	1710	groups
O	1710	1711	,
O	1712	1716	even
O	1717	1722	after
O	1723	1733	completing
O	1734	1743	treatment
O	1743	1744	.

O	1745	1747	At
O	1748	1751	the
O	1752	1755	end
O	1756	1758	of
O	1759	1762	the
O	1763	1765	12
O	1765	1766	-
O	1766	1770	week
O	1771	1779	exercise
O	1780	1787	program
O	1787	1788	,
O	1789	1792	the
O	1793	1801	exercise
O	1802	1807	group
O	1808	1811	had
O	1812	1816	less
B-outcome	1817	1824	fatigue
O	1825	1829	than
O	1830	1833	the
O	1834	1843	attention
O	1843	1844	-
O	1844	1851	control
O	1852	1857	group
O	1857	1858	,
O	1859	1862	and
O	1863	1867	this
O	1868	1873	group
O	1874	1884	difference
O	1885	1888	was
O	1889	1899	maintained
O	1900	1903	for
O	1904	1907	the
O	1908	1913	whole
O	1914	1919	study
O	1920	1926	period
O	1926	1927	.

O	1928	1930	At
O	1931	1934	the
O	1935	1938	end
O	1939	1941	of
O	1942	1950	exercise
O	1951	1958	program
O	1958	1959	,
O	1960	1965	women
O	1966	1969	who
O	1970	1973	had
O	1974	1979	spent
O	1980	1984	more
O	1985	1989	time
O	1990	2000	exercising
O	2001	2007	before
O	2008	2017	diagnosis
O	2018	2021	had
O	2022	2026	less
B-outcome	2027	2034	fatigue
O	2035	2039	than
O	2040	2045	those
O	2046	2049	who
O	2050	2053	had
O	2054	2063	exercised
O	2064	2068	less
O	2069	2074	often
O	2074	2075	.

O	2076	2078	In
O	2079	2087	addition
O	2087	2088	,
O	2089	2097	patients
O	2097	2098	'
O	2099	2106	fatigue
O	2107	2113	levels
O	2114	2116	at
O	2117	2124	various
O	2125	2129	time
O	2130	2136	points
O	2137	2147	fluctuated
O	2148	2153	along
O	2154	2158	with
O	2159	2164	their
B-outcome	2165	2175	functional
I-outcome	2176	2187	performance
I-outcome	2187	2188	,
I-outcome	2189	2194	sleep
I-outcome	2195	2206	disturbance
I-outcome	2206	2207	,
I-outcome	2208	2211	and
I-outcome	2212	2222	depression
O	2222	2223	.

O	2224	2227	Our
O	2228	2236	tailored
O	2236	2237	,
O	2238	2242	home
O	2242	2243	-
O	2243	2248	based
O	2249	2254	brisk
O	2255	2262	walking
O	2263	2270	program
O	2271	2282	effectively
O	2283	2290	reduced
O	2291	2298	fatigue
O	2299	2301	in
O	2302	2308	breast
O	2309	2315	cancer
O	2316	2324	patients
O	2325	2330	under
O	2331	2343	chemotherapy
O	2343	2344	,
O	2345	2348	and
O	2349	2353	this
O	2354	2360	effect
O	2361	2367	lasted
O	2368	2373	after
O	2374	2384	completing
O	2385	2394	treatment
O	2394	2395	.
